New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 28, 2012
07:34 EDTCPHDCepheid 2013 sales of CT/NG estimated $15M-$20M at William Blair
William Blair expects solid initial demand for Cepheid's just approved Xpert CT/NG from existing Xpert customers and projects 2013 sales between $15M-$20M on a worldwide basis. However, William Blair says it is not sure if Cepheid will be able to ship enough product to meet initial demand as it provided no update on the recent manufacturing issues. The firm keeps an Outperform rating on the stock.
News For CPHD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 28, 2014
07:22 EDTCPHDCepheid to collaborate with FIND and Rutgers for novel tuberculosis test
Cepheid, FIND, and Rutgers New Jersey Medical School, will collaborate to develop Xpert MTB/RIF Ultra, a next-generation test for Mycobacterium tuberculosis with increased sensitivity to aid in detection of patients with smear-negative TB, which is often associated with HIV co-infection. The collaboration is also receiving additional support from the National Institute of Allergy and Infectious Diseases at the NIH. Xpert MTB/RIF Ultra is expected to be available to the HBDC market in 1H16.
October 16, 2014
17:35 EDTCPHDCepheid 'well positioned' to address Ebola
Subscribe for More Information
17:28 EDTCPHDCepheid sees Q4 adjusted EPS 2c-4c, may not compare to consensus (9c)
Subscribe for More Information
16:11 EDTCPHDCepheid sees FY14 adjusted EPS 11c-13c, may not compare to consensus (52c)
Subscribe for More Information
16:09 EDTCPHDCepheid reports Q3 EPS ex-items 6c, consensus (16c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use